Results 61 to 70 of about 5,090 (179)

Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanomaResearch in context

EBioMedicine, 2019
Background: Talimogene laherparepvec (T-VEC) is an intralesionally delivered, modified herpes simplex virus type-1 oncolytic immunotherapy. The biodistribution, shedding, and potential transmission of T-VEC was systematically evaluated during and after ...
Robert H.I. Andtbacka, Thomas Amatruda, John Nemunaitis, Jonathan S. Zager, John Walker, Jason A. Chesney, Kate Liu, Cheng-Pang Hsu, Cheryl A. Pickett, Janice M. Mehnert   +9 more
doaj   +1 more source

A systematic analysis on the clinical safety and efficacy of onco-virotherapy [PDF]

, 2021
Several onco-virotherapy candidates have been developed and clinically evaluated for the treatment of cancer, and several are approved for clinical use.
Bhatt, Darshak K., Carvalho Barros, Luciana Rodrigues, Chammas, Roger, Daemen, Toos, Wekema, Lieske   +4 more
core   +1 more source

Oncolytic Therapy: Delivery System and New Therapeutic Strategies for Cancer

MedComm, Volume 7, Issue 4, April 2026.
This review summarizes recent advances in nanoparticle‐ and cell‐mediated OVs delivery strategies that improve biodistribution and tumor targeting while limiting immune clearance. It also examines combination approaches that enhance therapeutic efficacy through tumor microenvironment modulation or immune activation, thereby overcoming immunosuppression
Sikan Jin, Yi Zhang, Ziling Zhou, Yaqi Zhang, Ting Yu, Rui Xu, Lin Xu, Jidong Zhang, Longze Zhang, Shan Yang, Xianyao Wang   +10 more
wiley   +1 more source

Oncolytic virus therapy in early metastatic melanoma:The importance of adequate staging [PDF]

, 2023
Talimogene laherparepvec (T-VEC) is a modified herpes simplex virus, type 1, which can be administered intralesionally in patients with unresectable metastatic melanoma.
Franke, V.
core  

Neoadjuvant therapy in skin cancer: current evidence and future perspectives

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 4, Page 454-462, April 2026.
Summary The development of immune checkpoint inhibitors and targeted therapies has fundamentally changed the treatment of cutaneous malignancies, especially in squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The latest neoadjuvant approaches have shown promising results in locally advanced stages.
Lea Daniello, Johannes Kleemann, Bastian Schilling   +2 more
wiley   +1 more source

Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies [PDF]

, 2016
Encouraging results from recent clinical trials are revitalizing the field of oncolytic virotherapies. Human adenovirus type 5 (HAdV-C5/Ad5) is a common vector for its ease of manipulation, high production titers and capacity to transduce multiple cell ...
Chester, John, Curtis, Sarah, Davies, James, Parker, Alan, Uusi-Kerttula, Hanni   +4 more
core   +1 more source

Neoadjuvante Therapie bei Hautkrebs: aktuelle Datenlage und Ausblicke

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 4, Page 454-463, April 2026.
Zusammenfassung Die Entwicklung von Immuncheckpoint‐Inhibitoren sowie zielgerichteten Therapien hat die Behandlung von Hauttumoren, vor allem des kutanen Plattenepithelkarzinoms, Melanoms und Merkelzellkarzinoms, grundlegend verändert. Neuste neoadjuvante Ansätze zeigen besonders bei lokal fortgeschrittenen Stadien nun praxisrelevante Ergebnisse.
Lea Daniello, Johannes Kleemann, Bastian Schilling   +2 more
wiley   +1 more source

Clinical Application of Oncolytic Viruses: A Systematic Review [PDF]

, 2020
Leveraging the immune system to thwart cancer is not a novel strategy and has been explored via cancer vaccines and use of immunomodulators like interferons.
Chauhan, Aman, Cook, Mary
core   +2 more sources

Immune Exhaustion in Chronic Infection and Cancer: Signaling Pathways and Therapeutic Interventions

MedComm, Volume 7, Issue 3, March 2026.
Immune exhaustion is a well‐established hallmark of both cancer and chronic infection. This review proposes a novel “infection–exhaustion–tumor axis” framework, wherein chronic pathogens (e.g., oncogenic viruses) evade immune surveillance by hijacking inflammatory signaling to drive immune cell exhaustion, thereby creating immunosuppressive niches ...
Yali Song, Yazhi Mo, Si Chen, Yuemei Chen, Chunying Zhang, Shanying Deng, Juan Liao, Yi He, Wei Wang, Weidong Zheng, Tingting Zeng   +10 more
wiley   +1 more source

Drug Delivery Systems for Resiquimod to Control Myeloid‐Derived Suppressor Cells in Cancer Immunotherapy

WIREs Nanomedicine and Nanobiotechnology, Volume 18, Issue 2, March/April 2026.
Myeloid‐derived suppressor cells (MDSCs) are key contributors to cancer immunotherapy failure and major targets in new therapeutic strategies. We highlight therapeutic approaches to counteract their immunosuppressive functions and discuss recent efforts to optimize drug delivery for controlling MDSCs, focusing on resiquimod as a representative drug ...
Yanying He, Yoon Yeo
wiley   +1 more source